Invoice No VAT Registration No. GB 630 969 813



INVOICE TO

Cabinet Office

Government Chief Commerical Officer 1 Horse Guards Road London SW1A 2HQ

DELIVER TO

Critical Care Research Office Dr University College Hospital Maple House, Link Bridge Corridor, 3rd Floor 235 Euston Road London NW1 2BU

Customer VAT No Your Order No. Account No OA No Date Shipped Invoice Date PO/F/9843 30 - Mar - 20 30 - Mar - 20

ORDER CODE	DESCRIPTION	Unit Price Qty GBP	Line Total GBP
FLO_OX	Continuous Oxygen CPAP Monitor VAT Zero Rating Certificate supplied		137,100.00
		NET VAT AMOUNT DUE GBI	137,100.00 0.00 137,100.00

PAYMENT TERMS: Strictly net 15 days from Invoice date by cheque, BACS or wire transfer E&OE TERMS AND CONDITIONS: Copy of our standard Terms and Conditions available on request.

Sterling Wire transfer:	
Euro Wire Transfer:	, SEE THE SERVICE OF
JS\$ Wire transfer:	

Signatu CEO Country of Origin UK

F2800-8 rev1

Issue Date: xx/06/11

Oxford Optronix Ltd 19-21 Central 127, Milton Park Oxford, OX14 4SA, UK

e: info@oxford-optronix.com

w: www.oxford-optronix.com

UK t: 0870 2000 199 f: 0870 2000 188

International t: +44 1235 821 803 f: +44 1235 821 678

1 Horse Guards Road London SW1A 2HQ

UCL Gower St Bloomsbury London WC1E 6BT

26 March 2020

Dear ,

RE: CPAP Devices - Letter of Commitment

Many thanks to you and your team for the excellent efforts that you have put into responding to the crucial Ventilator Challenge. Whilst this device does not meet the published specification, the ventilation challenge team have agreed to look at it as is fulfils a complimentary clinical purpose. We would therefore like to give you and your supply chain confidence to continue. Specifically:

- We commit to purchasing a proof of principle early manufacturing run of up to 100 devices, subject to MHRA approval, dependant on how many devices you want to test in UCL hospitals.
- We would like to support you as you activate your supply chain and we urge your manufacturers to prioritise components that can be used to produce ventilators. A letter has been prepared as such which we will share with you
- We would like to help you get any support you need to work with MHRA safety issues would need to be resolved before the devices could be put into clinical practice. MHRA approval will be needed.
- We would require a written report on safety before we agree to further manufacture.
- This is subject to proposed prices as discussed and agreed with the NHS we expect
 the pricing for the units to be in line with current prices paid by the NHS for these
 units.

Thanks again for your continued support.

Very kind regards,



Government Chief Commercial Officer.